Distinctive Drug Binding Sites and Gating Mechanisms of the Nociceptive Ion Channel TRPA1

Jun Chen,Tania Chernov-Rogan

DOI: https://doi.org/10.1016/j.bpj.2017.11.3458

IF: 3.4

2018-01-01

Biophysical Journal

Abstract:As an irritant sensor, TRPA1 channel has emerged as a therapeutic target for pain, itch and respiratory diseases. It has been reported that a plethora of electrophilic agonists, such as allyl isothiocyanate, activate TRPA1 through covalent modification of cysteine residues (e.g., C621); and A-967079, an antagonist, binds to the pore domain through induced fit. Despite these progresses, it remains largely unknown how covalent modification leads to channel opening, and how non-reactive agonists and other antagonists interact with the channel. From high throughput screening and structure-function studies, we have discovered several classes of TRPA1 modulators and determined critical residues/domains, including N-ter, PreS1, TM1-4, pore and C-ter domain of the channel. For examples, G6828, a reactive agonist, modifies C621 residue but its functional effect is mediated by PreS1 -helix, indicating that PreS1 domain couples covalent modification (in the N-ter) to channel opening (pore). G1243, a non-covalent agonist, activates TRPA1 by binding to TM1-4 domain, a site equivalent to the capsaicin binding site in TRPV1. Therefore, TRPA1 and TRPV1 may share similar gating mechanism despite the lack of sequence homology. Together, these data shed light on the structure-function of TRPA1 and provide insights to rational drug design.